We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+9.09%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$18.6B
AUM Growth
+$370M
(+2%)
Cap. Flow
-$1.05B
Cap. Flow
% of AUM
-5.64%
Top 10 Holdings %
Top 10 Hldgs %
19.87%
Holding
1,286
New
95
Increased
394
Reduced
580
Closed
90
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$42.1M |
| 2 |
Amazon
AMZN
|
+$37.3M |
| 3 |
Agilent Technologies
A
|
+$34.9M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$34.7M |
| 5 |
Netflix
NFLX
|
+$33.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Progressive
PGR
|
+$132M |
| 2 |
Cencora
COR
|
+$65.6M |
| 3 |
Biogen
BIIB
|
+$53.3M |
| 4 |
Applied Materials
AMAT
|
+$44.9M |
| 5 |
Dollar General
DG
|
+$44.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.39% |
| 2 | Healthcare | 13.06% |
| 3 | Financials | 11.34% |
| 4 | Consumer Discretionary | 9.35% |
| 5 | Industrials | 8.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Manulife Financial
MFC
$74.2B
| $371K | ﹤0.01% |
17,293
-18,594
| -52% | -$370K |
|
|
TCRR
927
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $371K | ﹤0.01% |
16,806
+256
| +2% | +$6.98K |
|
|
DCPH
928
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $366K | ﹤0.01% |
8,171
+117
| +1% | +$5.45K |
|
929
Gen Digital
GEN
$16.5B
| $362K | ﹤0.01% |
17,078
-5,365
| -24% | -$112K |
|
930
BWX Technologies
BWXT
$15.5B
| $361K | ﹤0.01% |
5,482
-300
| -5% | -$18K |
|
931
Omega Flex
OFLX
$306M
| $360K | ﹤0.01% |
2,284
+404
| +21% | +$63.5K |
|
932
Choice Hotels
CHH
$5.22B
| $359K | ﹤0.01% |
3,352
-636
| -16% | -$67.8K |
|
933
First Financial Bankshares
FFIN
$5.05B
| $357K | ﹤0.01% |
7,668
+58
| +0.8% | +$2.52K |
|
934
Ligand Pharmaceuticals
LGND
$5.94B
| $357K | ﹤0.01% |
3,757
-2,750
| -42% | -$260K |
|
935
iShares Currency Hedged MSCI EAFE ETF
HEFA
$7.51B
| $356K | ﹤0.01% |
10,817
| – | – |
|
936
Beam Therapeutics
BEAM
$2.7B
| $355K | ﹤0.01% |
4,440
+1,440
| +48% | +$137K |
|
937
Datadog
DDOG
$89.3B
| $352K | ﹤0.01% |
+4,238
| New | +$409K |
|
|
XLNX
938
DELISTED
Xilinx Inc
XLNX
| $352K | ﹤0.01% |
2,851
-134,117
| -98% | -$17.9M |
|
939
Toyota
TM
$221B
| $351K | ﹤0.01% |
2,255
+10
| +0.4% | +$1.51K |
|
940
Verisk Analytics
VRSK
$27.8B
| $351K | ﹤0.01% |
1,991
-355
| -15% | -$65K |
|
941
Brown-Forman Class A
BF.A
$13.4B
| $350K | ﹤0.01% |
5,508
-145
| -3% | -$9.89K |
|
|
IGMS
942
DELISTED
IGM Biosciences
IGMS
| $348K | ﹤0.01% |
4,542
+1,712
| +60% | +$156K |
|
943
WD-40
WDFC
$3.08B
| $348K | ﹤0.01% |
1,139
-2,912
| -72% | -$883K |
|
944
Deutsche Bank
DB
$67.6B
| $346K | ﹤0.01% |
28,908
-355
| -1% | -$4.15K |
|
945
FIVE9
FIVN
$2.08B
| $346K | ﹤0.01% |
2,223
+181
| +9% | +$30.9K |
|
|
DRNA
946
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $345K | ﹤0.01% |
13,513
+223
| +2% | +$5.7K |
|
947
Lamb Weston
LW
$7.51B
| $344K | ﹤0.01% |
4,459
-313
| -7% | -$24.7K |
|
|
PPLI
948
People Inc
PPLI
$3.13B
| $340K | ﹤0.01% |
2,889
-57
| -2% | -$7.08K |
|
949
Atlantic Union Bankshares
AUB
$6.11B
| $337K | ﹤0.01% |
8,805
+71
| +0.8% | +$2.62K |
|
950
Central Garden & Pet Co Class A
CENTA
$2.44B
| $337K | ﹤0.01% |
8,134
| – | – |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q1 2021 Portfolio in Review
As of Q1 2021, Glenmede Trust held 1,286 positions worth $18.6B, up 2% from $18.2B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Glenmede Trust withdrew a net $1.05B in Q1 2021, closing 90 positions and reducing 580 holdings. Its most notable exit was Coherent, an estimated $32.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Glenmede Trust opened a new position in Rollins worth $29.6M.
- Glenmede Trust's largest Q1 2021 buy was Rollins: 860,755 shares worth $29.6M.
- Glenmede Trust added most to State Street SPDR S&P 500 ETF Trust in Q1 2021, an estimated $42.1M increase.
- Glenmede Trust's biggest Q1 2021 reduction was Progressive, cutting an estimated $132M.
- Glenmede Trust fully exited Coherent in Q1 2021, selling an estimated $32.9M.
- Glenmede Trust's ten largest holdings make up 20% of its $18.6B portfolio in Q1 2021.
- Glenmede Trust opened 95 new positions and closed 90 in Q1 2021.
- Glenmede Trust's portfolio value rose 2% quarter-over-quarter to $18.6B.
Based on Glenmede Trust's 13F filing for Q1 2021, filed 18 May 2021.